$RTSL
Rapid Therapeutic Science Laboratories, Inc. Stock $rtsl

$rtsl Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000139390523000220 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$97.74K	$92.30K	$762.1K
YoY Change	-3.34%	-87.89%	51.84%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$5.993K	$5.993K	$5.990K
YoY Change	0.0%	0.05%	-66.78%
% of Gross Profit
Operating Expenses	$103.7K	$98.29K	$789.4K
YoY Change	-19.2%	-87.55%	51.82%
Operating Profit	-$103.7K	-$98.29K	-$789.4K
YoY Change	-19.2%	-87.55%	51.82%
Interest Expense	$60.83K	$111.0K	-$713.3K
YoY Change	-92.05%	-115.56%	5068.91%
% of Operating Profit
Other Income/Expense, Net	$150.2K	$289.6K	-$77.05K
YoY Change	64.04%	-475.81%
Pretax Income	$46.42K	$191.3K	-$1.580M
YoY Change	-226.02%	-112.11%	195.97%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%
Net Earnings	$46.42K	$191.3K	-$1.580M
YoY Change	-226.02%	-112.11%	195.97%
Net Earnings / Revenue
Basic Earnings Per Share	$0.01	$0.02	-$0.20
Diluted Earnings Per Share	$0.01	$0.02	-$204.0K
COMMON SHARES
Basic Shares Outstanding	8.082M shares	7.882M shares	7.745M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.160K	$17.57K	$32.99K
YoY Change	-98.07%	-46.74%	-82.17%
Cash & Equivalents	$2.160K	$17.57K	$32.99K
Short-Term Investments
Other Short-Term Assets	$58.15K	$58.15K	$71.27K
YoY Change	-13.08%	-18.41%
Inventory	$175.0K	$175.0K	$175.1K
Prepaid Expenses	$58.15K	$58.15K
Receivables
Other Receivables
Total Short-Term Assets	$317.9K	$250.8K	$279.3K
YoY Change	-10.23%	-10.22%	-24.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.289M	$1.295M	$2.242M
YoY Change	-15.39%	-42.26%	265.34%
Goodwill
YoY Change
Intangibles	$170.1K	$170.1K
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.756M	$1.784M	$2.412M
YoY Change	-15.39%	-26.06%	207.76%
TOTAL ASSETS
Total Short-Term Assets	$317.9K	$250.8K	$279.3K
Total Long-Term Assets	$1.756M	$1.784M	$2.412M
Total Assets	$2.074M	$2.034M	$2.692M
YoY Change	-14.64%	-24.41%	132.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$770.0K	$734.8K	$1.200M
YoY Change	9.27%	-38.74%	2569.91%
Accrued Expenses	$274.5K	$248.5K	$136.9K
YoY Change	73.46%	81.55%	291.95%
Deferred Revenue
YoY Change
Short-Term Debt	$2.456M	$2.437M	$1.942M
YoY Change	10.15%	25.52%	7764.56%
Long-Term Debt Due	$841.6K	$830.0K	$683.7K
YoY Change	19.08%	21.4%	2784.81%
Total Short-Term Liabilities	$4.426M	$4.463M	$5.124M
YoY Change	-8.95%	-12.91%	3896.2%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities	$237.9K	$259.2K	$358.8K
YoY Change	-29.73%	-27.76%
Total Long-Term Liabilities	$387.9K	$409.2K	$508.8K
YoY Change	-20.6%	-19.57%	239.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.426M	$4.463M	$5.124M
Total Long-Term Liabilities	$387.9K	$409.2K	$508.8K
Total Liabilities	$4.813M	$4.872M	$5.633M
YoY Change	-10.01%	-13.51%	1924.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.08M	-$10.12M
YoY Change	-0.59%
Common Stock	$8.832K	$8.082K
YoY Change	14.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$337.3K	$337.3K
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	-$2.739M	-$2.838M	-$2.942M
YoY Change
Total Liabilities & Shareholders Equity	$2.074M	$2.034M	$2.692M
YoY Change	-14.64%	-24.41%	132.92%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$46.42K	$191.3K	-$1.580M
YoY Change	-226.02%	-112.11%	195.97%
Depreciation, Depletion And Amortization	$5.993K	$5.993K	$5.990K
YoY Change	0.0%	0.05%	-66.78%
Cash From Operating Activities	-$7.330K	-$41.81K	-$383.8K
YoY Change	-97.07%	-89.1%	-26.81%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$350.9K
YoY Change	-100.0%	-100.0%	1673.76%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$350.9K
YoY Change	-100.0%	-100.0%	1673.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-8.090K	$59.39K	575.1K
YoY Change	-102.43%	-89.67%	150.06%
NET CHANGE
Cash From Operating Activities	-7.330K	-$41.81K	-383.8K
Cash From Investing Activities	0.000	$0.00	-350.9K
Cash From Financing Activities	-8.090K	$59.39K	575.1K
Net Change In Cash	-15.42K	$17.57K	-159.5K
YoY Change	-119.47%	-111.02%	-49.23%
FREE CASH FLOW
Cash From Operating Activities	-$7.330K	-$41.81K	-$383.8K
Capital Expenditures	$0.00	$0.00	-$350.9K
Free Cash Flow	-$7.330K	-$41.81K	-$32.93K
YoY Change	-97.03%	26.98%	-93.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55018
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Rapid Therapeutic Science Laboratories, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2111820
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	558 County Road 472
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	De Leon
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76444
CY2023Q1	dei	City Area Code CityAreaCode	800
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	497-6059
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8082397	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17572	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	175047	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	175047	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	58146	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	58146	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	250765	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	233193	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1354072	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1564503	usd
CY2023Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	59320	usd
CY2022Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	53327	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1294752	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1511176	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318878	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	340136	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	170075	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	170075	usd
CY2023Q1	us-gaap	Assets Assets	2034470	usd
CY2022Q4	us-gaap	Assets Assets	2254580	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	734833	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	891408	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	829988	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	820602	usd
CY2023Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	2437310	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	2481333	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	148907	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	124736	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99580	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98509	usd
CY2023Q1	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	80520	usd
CY2022Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	508593	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	131700	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	40647	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4462838	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4965828	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	150000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	150000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259188	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	280235	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4872026	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5396063	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8082397	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7764594	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	8082	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7763	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7616579	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7504242	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10124878	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10316149	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	337339	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	337339	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2837556	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3141483	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2034470	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2254580	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2022Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	0	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92301	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	783400	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5993	usd
CY2022Q1	us-gaap	Depreciation Depreciation	5993	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	98294	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	789393	usd
CY2023Q1	fil	Gain Loss On Valuation Of Warrant Liability GainLossOnValuationOfWarrantLiability	400591	usd
CY2022Q1	fil	Gain Loss On Valuation Of Warrant Liability GainLossOnValuationOfWarrantLiability	-77045	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	111026	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	713313	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	289565	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-790358	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	191271	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1579751	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	191271	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1579751	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7979592	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7744544	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3141483	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	112656	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	191271	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2837556	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1381757	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1579751	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2941508	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	191271	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1579751	usd
CY2023Q1	fil	Gain Loss On Valuation Of Warrant Liability GainLossOnValuationOfWarrantLiability	400591	usd
CY2022Q1	fil	Gain Loss On Valuation Of Warrant Liability GainLossOnValuationOfWarrantLiability	-77045	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	30331	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	627047	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	51873	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	20000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5993	usd
CY2022Q1	us-gaap	Depreciation Depreciation	5993	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2233	usd
CY2023Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	21258	usd
CY2022Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	33880	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	132121	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	24171	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15890	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41814	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-699422	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35204	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35204	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	33587	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	400000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	50000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	175127	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	24201	usd
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59386	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	575127	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17572	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-159499	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	192484	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17572	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32985	usd
CY2023Q1	us-gaap	Interest Paid InterestPaid	0	usd
CY2022Q1	us-gaap	Interest Paid InterestPaid	0	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	112656	usd
CY2022Q1	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	0	usd
CY2023Q1	fil	Accounts Payable For Additions To Property And Equipment AccountsPayableForAdditionsToPropertyAndEquipment	-210431	usd
CY2022Q1	fil	Accounts Payable For Additions To Property And Equipment AccountsPayableForAdditionsToPropertyAndEquipment	307879	usd
CY2022Q1	fil	Common Stock Authorized Increase CommonStockAuthorizedIncrease	800000000	shares
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:10pt Times New Roman;margin:0;text-indent:36pt;text-align:justify"><i>Use of Estimates</i> - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.</p> <p style="font:10pt Times New Roman;margin:0;text-indent:36pt;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;text-indent:36pt;text-align:justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates.</p>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10124878	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1354072	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1564503	usd
CY2023Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	59320	usd
CY2022Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	53327	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1294752	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1511176	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	3417298	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	3451935	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	69599	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	102792	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	107075	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	111358	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99580	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259188	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318878	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	358768	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259188	usd
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.05	pure
CY2020Q1	fil	Common Stock Authorized Increase CommonStockAuthorizedIncrease	750000000	shares
CY2022Q1	fil	Common Stock Authorized Increase CommonStockAuthorizedIncrease	800000000	shares
CY2022Q1	fil	Preferred Stock Share Increase PreferredStockShareIncrease	100000000	shares

Files In Submission

Name	View Source	Status
rtsl-20230331_lab.xml	Edgar Link	unprocessable
0001393905-23-000220-index-headers.html	Edgar Link	pending
0001393905-23-000220-index.html	Edgar Link	pending
0001393905-23-000220.txt	Edgar Link	pending
0001393905-23-000220-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtsl-20230331.htm	Edgar Link	pending
rtsl-20230331.xsd	Edgar Link	pending
rtsl10q_1.jpg	Edgar Link	pending
rtsl_ex311.htm	Edgar Link	pending
rtsl_ex312.htm	Edgar Link	pending
rtsl_ex321.htm	Edgar Link	pending
rtsl_ex322.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rtsl-20230331_cal.xml	Edgar Link	unprocessable
rtsl-20230331_def.xml	Edgar Link	unprocessable
rtsl-20230331_pre.xml	Edgar Link	unprocessable
rtsl-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RTSL
Rapid Therapeutic Science Laboratories, Inc. Stock $rtsl

2023 Q2 Form 10-Q Financial Statement

#000139390523000220 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RTSL Rapid Therapeutic Science Laboratories, Inc. Stock $rtsl

2023 Q2 Form 10-Q Financial Statement

#000139390523000220 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RTSL
Rapid Therapeutic Science Laboratories, Inc. Stock $rtsl